September 15, 2014 11:04 PM ET

Pharmaceuticals

Company Overview of Oramed Pharmaceuticals Inc.

Company Overview

Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as...

Hi-Tech Park 2/4

Givat-Ram

PO Box 39098

Jerusalem,  91390

Israel

Founded in 2002

Phone:

972 2 566 0001

Fax:

972 2 566 0004

Key Executives for Oramed Pharmaceuticals Inc.

Chief Executive Officer
Age: 40
Total Annual Compensation: $259.7K
Chief Financial Officer
Age: 40
Total Annual Compensation: $98.4K
Chief Operating Officer and Vice President of Business Development
Age: 44
Total Annual Compensation: $48.4K
Chief Medical & Technology Officer and Director
Age: 74
Total Annual Compensation: $188.4K
Compensation as of Fiscal Year 2013.

Oramed Pharmaceuticals Inc. Key Developments

Oramed Pharmaceuticals Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 10:00 AM

Oramed Pharmaceuticals Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-09-2014 10:00 AM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.

Oramed Pharmaceuticals Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:00 AM

Oramed Pharmaceuticals Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-11-2014 09:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.

Oramed Pharmaceuticals Inc. Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes

Oramed Pharmaceuticals Inc. reported that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study in patients with established type 1 diabetes is evaluating the safety and impact of ORMD-0801 on the exogenous insulin requirements in 24 type 1 diabetics patients.

Similar Private Companies By Industry

Company Name Region
Minerva Cardionet Ltd. Middle East/Africa
Yamit Biotechnologies Ltd. Middle East/Africa
Nanolymf Ltd. Middle East/Africa
Perrigo Israel Pharmaceuticals Limited Middle East/Africa
NeuroDerm Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oramed Pharmaceuticals Inc., please visit www.oramed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.